Exelixis | EXEL - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bayer EUR 1.11B 1.65B 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 235.91M 20.45M 2025-12
Genmab DKK 260M 199M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sanofi EUR 1.5B 2.29B 2025-12
Takeda JPY 168.82B 479.89B 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Xencor USD -53.63M 6.11M 2025-12